ClinicalTrials.gg
Not yet recruitingNCT07649369Updated Jun 16, 2026

A Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion

A Phase 2 interventional study of JMKX000197 and Cisplatin in Malignant Pleural Effusions (Mpe), sponsored by Shanghai Jeyou Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Shanghai Jeyou Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies in Pleural Effusion, Malignant with a site in China — 14 open to participants now, 15 under way, 1 of them phase 3. Pleural Effusion, Malignant · China.

Planned enrollment
7th of 28
120 · median 75
Started
2026
with 5 others
Phase 2
9 of 30
1 open now
Primary completion
2028-01
later than 10 of 14 live
Registered
29th of 30
by date

Among the 30 studies in Pleural Effusion, Malignant with a site in China, this one is the 7th largest by planned enrollment of the 28 interventional ones that give a count, is one of 6 that started in 2026, is one of 9 in phase 2, reaches primary completion later than 10 of the 14 other live ones, and was the 29th registered.

Pleural Effusion, Malignant

169 studies on the registry are indexed under Pleural Effusion, Malignant; 39 are open to participants now.

Browse Pleural Effusion, Malignant studies →

Open to participants now

14 of the 30 studies in Pleural Effusion, Malignant with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 25 Pleural Effusion, Malignant studies recruiting now, 15 (60%) set no upper age limit and 5 (20%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Pleural Effusion, Malignant with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy and safety of intrapleural JMKX000197 compared with intrapleural cisplatin in patients with malignant pleural effusion.

03

Conditions studied

  • Malignant Pleural Effusions (Mpe)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with advanced solid tumors diagnosed by histopathology or cytopathology.
  • Moderate to large pleural effusions require intervention.
  • performance status: 0 to 2.
  • ≥ 3 months
  • Adequate organ function.
  • The serum pregnancy test of female participants of should be negative within 7 days prior to enrollment and must not be breastfeeding. With a fertile female/male must agree to use medically accepted non-pharmacological during the study and for 6 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  • Bilateral pleural effusion or concurrent peritoneal effusion, or concurrent pericardial effusion.
  • Pleural effusion is either encapsulated or severely separated; Or merge with chylothorax; Or combined with infectious pleural effusion.
  • Known allergies to the study drug or its components.
  • Have participated in other clinical trials within 28 days prior to randomization.
  • Major surgery within 28 days prior to randomization.
  • Central nervous system disease, , or cord compression.
  • Clinical unstable or uncontrolled concomitant cardiovascular, pulmonary, hepatic, renal or seizures diseases.
  • Active infections that require systemic treatment.
  • Have a history of organ transplantation.
  • Any further condition which, in the opinion of the Investigator, the participant is not suitable in the present study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Arm A

    JMKX000197

    Drug: JMKX000197

  • Experimental
    Arm B

    JMKX000197

    Drug: JMKX000197

  • Active comparator
    Arm C

    Cisplatin

    Drug: Cisplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Puncture/drainage - Free Survival (PuFS)

    Time frame: From the date of chest tube removal after the last dose of treatment until the date of next puncture /drainage or date of death from any cause, whichever come first, up to approximately 24 months

Secondary outcomes

  1. Pleural effusion overall response (ORR)

    Time frame: Up to approximately 24 months

  2. Overall survival (OS)

    Time frame: Up to approximately 24 months

  3. AEs or SAEs

    Time frame: Up to approximately 29 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Jan 2028, 16 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2026
First posted
Jun 16, 2026
StartEst.
Aug 17, 2026
Primary completionEst.
Jan 12, 2028
CompletionEst.
Aug 14, 2028
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07649369
Responsible party
Sponsor
First posted
Jun 16, 2026
Start date
Aug 17, 2026 (estimated)
Primary completion
Jan 12, 2028 (estimated)
Completion
Aug 14, 2028 (estimated)
Last update
Jun 16, 2026

Study contacts

Yujia Song
Contact
songyujia@jeyoupharma.com
+8615640506016
Jie Wang
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JMKX000197

Start the discussion